JENBURKT PHARMACEUTICALS LTD.

Jenburkt Pharmaceuticals Ltd announced the re-appointment of Shri. Dilip H. Bhuta as Whole Time Director and Chief Financial Officer (CFO) for a term of five years, effective April 1, 2027, to March 31, 2032. The shareholders approved this re-appointment at the 41st Annual General Meeting (AGM). The company also secured approval for remuneration payment for a three-year period from April 1, 2027, to March 31, 2030. Shri. Bhuta, aged 74, has been with the company since 2013 and brings extensive banking experience.

Jenburkt Pharmaceuticals Limited conducted its 41st Annual General Meeting (AGM) on September 4, 2026, entirely through Video Conference/Other Audio-Visual Means (VC/OAVM). The meeting commenced at 3:30 PM IST and concluded at 4:50 PM IST. The company facilitated remote e-voting for shareholders from September 1st to September 3rd, 2026, with an option for in-meeting voting. The proceedings included introductions from the board and auditors, and the Chairman highlighted the company's 41-year journey themed "Ripples of Change," emphasizing consistent decisions rooted in integrity and purpose. Statutory and secretarial auditors' reports were presented without adverse qualifications.

Jenburkt Pharmaceuticals Ltd has announced the elevation of Shri. Prem Ashish Bhuta from Management Associate to Associate Vice President (AVP) – Strategic Initiatives. This change in senior management is effective from September 4, 2026, following the recommendation of the Nomination and Remuneration Committee and prior approval of the Audit Committee. Shri. Prem Ashish Bhuta, aged 26, holds a Master of Science in Integrated Marketing from New York University and a Bachelor of Commerce (Honours) from Narsee Monjee Institute of Management Studies. He brings over 5 years of experience in finance, sales, marketing, and technology initiatives within the pharmaceutical sector. He is related to Shri. Ashish U. Bhuta, the Promoter and Chairman & Managing Director of the Company. His new role will focus on identifying, evaluating, and driving strategic initiatives across functions.

Jenburkt Pharmaceuticals Ltd announced its standalone unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the results in a meeting held on August 6, 2026. The company operates exclusively in the Pharmaceuticals business segment, making segment-wise reporting not applicable. The financial results were reviewed by the Audit Committee and approved by the Board.

Jenburkt Pharmaceuticals' standalone PAT fell 24.5% YoY to ₹5.89 Cr (from ₹7.79 Cr) even as revenue from operations was effectively flat YoY at ₹35.51 Cr (-0.04%, from ₹35.53 Cr) — a pure margin story, not a demand one. Sequentially the decline is sharper (PAT -45.8% QoQ, revenue -20.4% QoQ) but that mostly reflects Q4 being the seasonally heavier, year-end quarter for the business rather than a fresh deterioration. The squeeze sits almost entirely on the employee-cost line: employee benefit expenses rose to ₹13.03 Cr, up 11.1% YoY and a sharp 36.9% QoQ (from ₹9.52 Cr in Q4 FY26 and ₹11.72 Cr in Q1 FY26), pushing total expenses up 10.4% YoY to ₹30.26 Cr against near-flat revenue. Net profit margin compressed to 15.9% of total income from 20.7% a year ago and 22.2% last quarter; operating margin (PBT plus finance cost and depreciation, excluding other income, over revenue) fell to 17.0% from 25.2% YoY and 23.1% QoQ. EPS tracked the profit decline, at ₹13.34 versus ₹17.66 YoY and ₹24.58 QoQ, on an unchanged equity base of ₹4.41 Cr. There is no consensus street estimate available for this print — Jenburkt is a micro-cap with no visible analyst coverage or published Q1 FY27 preview — so vsStreet is unknown rather than a genuine miss/beat. Management has issued no formal prior guidance or outlook on record, and no press release accompanying this result was available beyond the standard BSE outcome letter, so there is no management framing to reconcile against the numbers. Corporate developments this quarter are largely administrative rather than operational: the board fixed August 28, 2026 as the record date for the previously recommended ₹20.70/share FY26 dividend, submitted the FY26 annual report, and scheduled the 41st AGM for September 4, 2026; none of these bear directly on the quarter's operating performance. On a full-year basis FY26 revenue had grown 13% and PAT 8.3%, so this quarter's flat topline and cost-driven profit decline is a step down from that run-rate — the key question going into Q2 FY27 is whether the employee-cost jump is a one-quarter step-up (increments, hiring) or a new higher base.

Jenburkt Pharmaceuticals Ltd has announced its 41st Annual General Meeting (AGM) will be held on Friday, September 4, 2026, at 3:30 p.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company has also shared its Annual Report for the financial year 2025-26, which includes the AGM notice, audited financial statements, cash flow statements, Directors' report, management discussion and analysis, auditors' report with an unmodified opinion, and a report on Corporate Governance. The Annual Report is being distributed electronically as per regulatory guidelines, with a web-link provided for members who have not registered their email addresses. The report highlights the company's long-standing commitment to CSR, rooted in its founding family's values.

Jenburkt Pharmaceuticals Ltd has submitted its Annual Report for the Financial Year 2025-26. The report includes audited standalone financial statements, the auditors' report, directors' report, and the notice for the 41st Annual General Meeting (AGM). The AGM is scheduled for September 4, 2026, at 3:30 p.m. IST, to be held via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The report also details the company's commitment to CSR, stemming from its founder's philosophy of giving back to the community, with initiatives dating back to the 1950s. The Annual Report is being disseminated electronically as per regulatory guidelines.

Jenburkt Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 6, 2026. The primary agenda item for this meeting is to consider and approve the standalone unaudited financial results for the quarter ending June 30, 2026. This announcement follows a previous communication dated June 18, 2026. The meeting will be held at Nirmala Apartments, 93, Jay Prakash Road, Andheri (West), Mumbai.

Jenburkt Pharmaceuticals Ltd has announced the shifting of its registered office within the local limits of Mumbai. The move, approved by the Board of Directors via a circular resolution on July 13, 2026, is effective from July 21, 2026. The new address is 14th floor, Unicorn, Dattaji Salvi Marg, off Veera Desai Road, Andheri West, Mumbai- 400 053, relocating from Nirmala Apartments, 93, Jay Prakash Road, Andheri West, Mumbai 400 058. The company has confirmed that there is no change in the Registrar of Companies (ROC) jurisdiction, and contact details like telephone number, email, and website remain the same.

Jenburkt Pharmaceuticals Limited has announced the closure of its trading window for all designated persons, insiders, and connected individuals, including their relatives. This closure is in effect from July 1, 2026, and will remain open 48 hours after the dissemination of the standalone unaudited financial results for the quarter ending June 30, 2026. The company will separately inform the exchange about the board meeting schedule to consider these financial results.